Sign in
ELEV Stock Price, Chart, Stats & News
Elevation Oncology, Inc.
Save
21.63M
Market cap
–
Current P/E
–
Forward P/E
ELEV chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 23.68% |
Operating margin | -100228.95% |
Pretax margin | -98686.84% |
Net margin | -98757.89% |
Effective tax rate | -0.07% |
ROA | -45.64% |
ROE | -63.93% |
D/E | 0.67x |
Interest coverage ratio | -13.24x |
ELEV valuation
P/E | – |
P/S | 569.14x |
P/B | 0.46x |
P/CF | -0.69x |
P/FCF | -0.69x |
P/OCF | -0.69x |
PEG | 0.47x |
EV multiple | -1.38x |
About
Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company operating in the United States, committed to developing targeted cancer therapies for patients with specific genetic profiles. Its leading drug candidate is seribantumab, an anti-HER3 monoclonal antibody currently being evaluated in the Phase II CRESTONE trial. This study focuses on treating advanced solid tumors that harbor a neuregulin-1 fusion.
Similar securities
Based on sector and market capitalization
Report issue